Safety and immunogenicity of H5N1 vaccine

Lancet

Volumn 368, Issue 9554, 2006, Pages 2209-2210

  Authier, FJ ^a   Gherardi, RK ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; INACTIVATED VACCINE; INFLUENZA VACCINE;

CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FASCIITIS; FATIGUE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LETTER; MACROPHAGE; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TH2 CELL;

EID: 33845800782     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69891-7     Document Type: Letter

References (5)

1. Bresson J., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/ 2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
2. Brewer J., Conacher M., Hunter C., Mohrs M., Brombacher F., and Alexander J. Aluminum hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4 and IL-13-mediated signaling. J Immunol 163 (1999) 6448-6454
3. Gherardi R., and Authier F. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin N Am 23 (2003) 699-712
4. Clements C., and Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20 (2002) S24-S33
5. Del Giudice G., Podda A., and Rappuoli R. What are the limits of adjuvanticity?. Vaccine 20 (2002) S38-S41